HAS
30
2
BBY
40
3
HUM
48
6
MDLZ
34
2
JWN
40
-2
SYF
85
2
AZO
46
-3
GM
65
-3
CAG
30
4
EXC
54
-2
DNB
78
6
ADP
64
2
NI
75
2
CINF
47
2
DHR
35
3
COP
56
2
EQR
54
-2
CAH
47
3
HOG
29
-4
UHS
54
3
HAS
30
2
BBY
40
3
HUM
48
6
MDLZ
34
2
JWN
40
-2
SYF
85
2
AZO
46
-3
GM
65
-3
CAG
30
4
EXC
54
-2
DNB
78
6
ADP
64
2
NI
75
2
CINF
47
2
DHR
35
3
COP
56
2
EQR
54
-2
CAH
47
3
HOG
29
-4
UHS
54
3
Financhill
Back

Amicus Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
25

FOLD
Amicus Therapeutics

Last Price:
9.51
Seasonality Move:
7.75%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Amicus Therapeutics Price Quote

$9.51
-0.08 (-0.83%)
(Updated: November 21, 2024 at 12:45 PM ET)

Amicus Therapeutics Key Stats

Sell
25
Amicus Therapeutics (FOLD) is a Sell
Day range:
$9.38 - $9.68
52-week range:
$9.02 - $14.57
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
5.93
P/B ratio:
16.14%
Volume:
2M
Avg. volume:
2.7M
1-year change:
-13.13%
Market cap:
$2.9B
Revenue:
$399.4M
EPS:
$-0.34

How Much Does Amicus Therapeutics Make?

Is Amicus Therapeutics Growing As A Company?

  • What Is Amicus Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.37%
  • What Is Amicus Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Amicus Therapeutics Stock Price Performance

What Is Amicus Therapeutics 52-Week High & Low?

Amicus Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Amicus Therapeutics?

Is Amicus Therapeutics Cash Flow Positive?

  • What Is FOLD Cash Flow From Operations?
    Cash flow from operations (TTM) is -$26.5M
  • What Is Amicus Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $12.2M
  • What Is Amicus Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$4.1M

Amicus Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    FOLD return on invested capital is -19.5%
  • What Is Amicus Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -13.78%
  • What Is FOLD Return On Equity?
    ROE is a measure of profitability and is -71.17%

Amicus Therapeutics Earnings Date & Stock Price

Amicus Therapeutics Competitors

  • Who Are Amicus Therapeutics's Competitors?
    Below is a list of companies who compete with Amicus Therapeutics or are related in some way:
    • Arbutus Biopharma Corp (ABUS)
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Ionis Pharmaceuticals Inc (IONS)
    • Krystal Biotech Inc (KRYS)
    • Tonix Pharmaceuticals Holding Corp (TNXP)

Amicus Therapeutics Dividend Yield

Amicus Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 91.02%
Revenue: 36.73% 4.86%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 17.75
Upside from Last Price: 85.09%

Major Shareholders

  • How many FOLD shares are owned by institutional investors?
    503.4M FOLD shares are owned by institutional investors
  • How many FOLD shares are owned by insiders?
    5.5M FOLD shares are owned by insiders